• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Guardian Pharmacy Services Inc.

    3/28/25 4:01:13 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $GRDN alert in real time by email
    8-K
    false 0001802255 0001802255 2025-03-24 2025-03-24

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 24, 2025

     

     

    Guardian Pharmacy Services, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware
      001-42284   87-3627139

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    300 Galleria Parkway SE  
    Suite 800  
    Atlanta, Georgia   30339
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (404) 810-0089

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Class A Common Stock, par value $0.001 per share   GRDN   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On March 24, 2025, the Compensation Committee (the “Committee”) of the Board of Directors of Guardian Pharmacy Services, Inc. (the “Company”) established the performance criteria and targets for the 2025 annual cash incentive awards (the “2025 Annual Incentive Program”) eligible to be earned by the Company’s executive officers under the Guardian Pharmacy Services, Inc. 2024 Equity and Incentive Compensation Plan.

    The performance metrics for the 2025 Annual Incentive Program consist of achieving specified goals for (i) 2025 Company revenue, weighted at 20%, (ii) 2025 Company Adjusted EBITDA, weighted at 60%, and (iii) geographic expansion of the Company’s business, weighted at 20%. The Committee established threshold, target and maximum performance goals for each metric. Performance at the threshold level would result in a payout of 75% of the executive officer’s target award amount, performance at the target level would result in a payout of 100% of the executive officer’s target award amount, and performance at the maximum level would result in a payout of 125% of the executive officer’s target award amount.

    The following table sets forth the respective award opportunities that the Company’s executive officers could earn based upon the achievement of the various performance criteria under the 2025 Annual Incentive Program:

     

         Payout Range ($)  

    Executive Officer

       Threshold      Target      Maximum  

    Fred Burke

    President and Chief Executive Officer

       $ 208,575      $ 278,100      $ 347,625  

    David Morris

    Executive Vice President and Chief Financial Officer

       $ 185,400      $ 247,200      $ 309,000  

    Kendall Forbes

    Executive Vice President, Sales & Operations

       $ 185,400      $ 247,200      $ 309,000  

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Guardian Pharmacy Services, Inc.
    March 28, 2025     By:  

    /s/ David K. Morris

        Name:   David K. Morris
        Title:  

    Executive Vice President and

    Chief Financial Officer

    Get the next $GRDN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRDN

    DatePrice TargetRatingAnalyst
    10/10/2025$30.00Outperform
    Oppenheimer
    10/21/2024$21.00Outperform
    Raymond James
    10/21/2024$22.00Buy
    Truist
    More analyst ratings

    $GRDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardian Pharmacy Services, Inc., to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call

    Guardian Pharmacy Services, Inc. (NYSE:GRDN) today announced that it will release fourth quarter and full-year 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call to discuss the results at 4:30 p.m. Eastern Time. Conference Call Details The conference call will be available via audio webcast at https://investors.guardianpharmacy.com and can also be accessed by dialing +1 (646) 564-2877 for U.S. participants, or +1 (800) 549-8228 for international participants, and referencing conference ID "93533." A replay will be available shortly after the call's completion and will remain available for approximately 60 days. About Guardian

    2/9/26 4:30:00 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Guardian Pharmacy Services Reiterates 2025 Guidance and Provides 2026 Outlook

    Presents Business Update at J.P. Morgan Healthcare Conference Guardian Pharmacy Services (NYSE:GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, is reiterating its previously announced 2025 guidance and providing its preliminary financial outlook for 2026. The Company expects to continue its low double-digit adjusted EBITDA growth trajectory in 2026, supported by the strength of its operating model and increased visibility into the year ahead, including anticipated drug pricing changes. The Company will review these and other business updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, J

    1/13/26 4:30:00 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Guardian Pharmacy Services, Inc. to Participate in Upcoming J.P. Morgan Healthcare Conference

    Guardian Pharmacy Services, Inc. (NYSE:GRDN) today confirmed the company will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The company's leadership team will host investor meetings on Wednesday, January 14th, and present at 4:30 p.m. PT the same day. A live audio webcast of the session will be available at https://investors.guardianpharmacy.com. A replay will be accessible shortly after the event and will remain available for 30 days. About Guardian Pharmacy Services Guardian Pharmacy Services is one of the nation's leading long-term care pharmacy services companies. Through its locally‑based business model, Guardian partners with long-term care

    12/15/25 4:30:00 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Guardian Pharmacy Services with a new price target

    Oppenheimer initiated coverage of Guardian Pharmacy Services with a rating of Outperform and set a new price target of $30.00

    10/10/25 8:37:40 AM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Raymond James initiated coverage on Guardian Pharmacy Services with a new price target

    Raymond James initiated coverage of Guardian Pharmacy Services with a rating of Outperform and set a new price target of $21.00

    10/21/24 8:25:47 AM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Truist initiated coverage on Guardian Pharmacy Services with a new price target

    Truist initiated coverage of Guardian Pharmacy Services with a rating of Buy and set a new price target of $22.00

    10/21/24 7:42:42 AM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Guardian Pharmacy Services Inc.

    SCHEDULE 13G/A - Guardian Pharmacy Services, Inc. (0001802255) (Subject)

    2/10/26 11:21:52 AM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Guardian Pharmacy Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Guardian Pharmacy Services, Inc. (0001802255) (Filer)

    1/13/26 4:41:45 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by Guardian Pharmacy Services Inc.

    SCHEDULE 13G/A - Guardian Pharmacy Services, Inc. (0001802255) (Subject)

    11/14/25 2:52:55 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Forbes Kendall gifted 21,500 shares, decreasing direct ownership by 3% to 790,976 units (SEC Form 4)

    4 - Guardian Pharmacy Services, Inc. (0001802255) (Issuer)

    12/8/25 4:10:02 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Officer Burke Fred gifted 200,000 shares, decreasing direct ownership by 12% to 1,511,845 units (SEC Form 4)

    4 - Guardian Pharmacy Services, Inc. (0001802255) (Issuer)

    12/8/25 4:10:04 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Cosler Steven D bought $99,786 worth of shares (3,370 units at $29.61), increasing direct ownership by 16% to 24,984 units (SEC Form 4)

    4 - Guardian Pharmacy Services, Inc. (0001802255) (Issuer)

    12/5/25 4:10:03 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cosler Steven D bought $99,786 worth of shares (3,370 units at $29.61), increasing direct ownership by 16% to 24,984 units (SEC Form 4)

    4 - Guardian Pharmacy Services, Inc. (0001802255) (Issuer)

    12/5/25 4:10:03 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Cosler Steven D bought $148,540 worth of shares (7,000 units at $21.22), increasing direct ownership by 65% to 17,713 units (SEC Form 4)

    4 - Guardian Pharmacy Services, Inc. (0001802255) (Issuer)

    11/20/24 4:05:12 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Salentine Thomas J Jr bought $499,996 worth of shares (35,714 units at $14.00) (SEC Form 4)

    4 - Guardian Pharmacy Services, Inc. (0001802255) (Issuer)

    10/1/24 5:48:50 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    Financials

    Live finance-specific insights

    View All

    Guardian Pharmacy Services, Inc., to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call

    Guardian Pharmacy Services, Inc. (NYSE:GRDN) today announced that it will release fourth quarter and full-year 2025 financial results after market close on Wednesday, March 11, 2026. Management will host a conference call to discuss the results at 4:30 p.m. Eastern Time. Conference Call Details The conference call will be available via audio webcast at https://investors.guardianpharmacy.com and can also be accessed by dialing +1 (646) 564-2877 for U.S. participants, or +1 (800) 549-8228 for international participants, and referencing conference ID "93533." A replay will be available shortly after the call's completion and will remain available for approximately 60 days. About Guardian

    2/9/26 4:30:00 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Guardian Pharmacy Services Reports Third Quarter 2025 Financial Results; Raises Full-Year Guidance

    Guardian Pharmacy Services, Inc. (NYSE:GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the third quarter ended September 30, 2025. The Company also raised its full-year revenue and Adjusted EBITDA guidance. Third Quarter Financial Results Revenue of $377.4 million, up 20% year-over-year. Residents served ended the quarter at approximately 204,000, up 13% year-over-year. Net Income (loss) of $9.6 million, compared to ($105.8) million in the prior-year period. Such year-over-year comparison is not meaningful due to income tax expense1 in the recently completed quarter, and certain one-time share-based

    11/10/25 4:05:00 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Guardian Pharmacy Services, Inc. to Report Third Quarter 2025 Financial Results and Host Conference Call

    Guardian Pharmacy Services, Inc. (NYSE:GRDN) announced today that it will release its third quarter 2025 results on Monday, November 10th, 2025, after market close and host a conference call to review the results at 4:30 pm ET. Conference Call Details The conference call will be available via audio webcast at https://investors.guardianpharmacy.com and can also be accessed by dialing (646) 564-2877 for U.S. participants, or +1 (800) 549-8228 for international participants, and referencing conference ID "11965." A replay will be available shortly after the call's completion and will remain available for approximately 60 days. About Guardian Pharmacy Services Guardian Pharmacy Services

    10/6/25 8:30:00 AM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardian Pharmacy Services Inc.

    SC 13G - Guardian Pharmacy Services, Inc. (0001802255) (Subject)

    12/6/24 12:05:09 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G filed by Guardian Pharmacy Services Inc.

    SC 13G - Guardian Pharmacy Services, Inc. (0001802255) (Subject)

    11/14/24 4:30:13 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G filed by Guardian Pharmacy Services Inc.

    SC 13G - Guardian Pharmacy Services, Inc. (0001802255) (Subject)

    11/14/24 1:01:24 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $GRDN
    Leadership Updates

    Live Leadership Updates

    View All

    Guardian Pharmacy Services, Inc. Names Ashley Ragsdale Stockton as Head of Investor Relations

    Guardian Pharmacy Services, Inc. ("Guardian") (NYSE:GRDN), one of the nation's largest and most innovative long-term care (LTC) pharmacy services companies is pleased to announce the appointment of Ashley Stockton as Senior Director, Head of Investor Relations. She will be responsible for leading the investor relations strategy and serving as the primary liaison with shareholders, analysts, and the broader investment community. Ashley joins Guardian with nearly thirty years of experience in equity markets. Most recently, she served as Head of Southeast Institutional Equity Sales for J.P. Morgan, where she built and managed strategic partnerships with institutional investors, delivering dif

    5/8/25 4:05:00 PM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Guardian Pharmacy Services Expands to New Jersey Through Partnership with Freedom Pharmacy

    Guardian Pharmacy Services, (NYSE:GRDN), one of the nation's largest and most innovative long-term care (LTC) pharmacy services companies, today announced that Freedom Pharmacy, an independent LTC pharmacy based in Randolph, New Jersey, is joining the Guardian family. The pharmacy will continue to operate under the name Freedom Pharmacy and serve residents in assisted living and skilled nursing, as well as individuals with intellectual and developmental disabilities throughout North, Northwest and Central New Jersey, with plans to further increase its presence across the Garden State in the future. This strategic partnership expands Guardian's Mid-Atlantic footprint and marks its first vent

    12/17/24 9:00:00 AM ET
    $GRDN
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples